Tests proton beam therapy, chemotherapy and liver transplant for bile duct cancer
Tests combined proton radiotherapy, chemotherapy and liver transplant in people with bile duct cancer.
Key facts
- Who runs it
- The Christie NHS Foundation Trust
- Where
- London and Manchester, United KingdomSee the 2 sites
- Trial code
- Registry title
- Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 3 Oct 2025
- Expected to end
- 1 Nov 2029
- Type of study
- Interventional
- Treatments tested
- Proton Beam Therapy
- Concurrent oral capecitabine chemotherapy
- Cisplatin & Gemcitabine intravenous chemotherapy
- Orthotropic Liver Transplant
- Record updated
- 10 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with bile duct cancer (hilar cholangiocarcinoma) that cannot be removed by surgery, who could have a liver transplant after proton beam therapy and chemotherapy.
- Age
- 17 years and over
- Sex
- All sexes
- Disease stage
- Bile duct cancer proven by cell or tissue testing, with a main narrowing of the bile duct at the liver hilum or a mass under 3cm (1.2 in) on imaging. No spread, including to nearby lymph nodes.
- Earlier treatment
- No radiation to the upper abdomen before. No bile duct surgery or hilar dissection in the past 12 months.
- Biomarker or test result
- A history of primary sclerosing cholangitis (PSC) is needed at the start. This may be widened later in the study.
Main reasons for not taking part
- Cancer outside the liver at any stage
- Another cancer in the last 5 years (some early cancers excepted)
- eGFR under 30
- Uncontrolled infection
- Cancer growing into the duodenum
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- General criteria
- Age 17 years and over
- Performance status 0 or 1 (Eastern Cooperative Oncology Group)
- Suitable for liver transplantation as determined by Multi Disciplinary Team (MDT)
- Able to tolerate neoadjuvant therapy
- A history of primary sclerosing cholangitis (PSC) will be a necessary eligibility criterion at the start of the study. Part-way through recruitment to the study, the eligibility criteria may be broadened, allowing patients with sporadic / non-PSC unresectable cholangiocarcinoma to also be considered. The decision to do this will be taken by the Study Management Group, who will be monitor results closely, following an interim analysis after the first 10 patients. Suitability for Orthotropic Liver Transplant will continue to be confirmed in the regional Hepato Biliary cancer MDT; Specific criteria
- Presence of a dominant hilar stricture or mass <3cm on cross-sectional imaging
- Histologically proven cholangiocarcinoma by brush cytology or biopsy via Endoscopic Retrograde Cholangiopancreatography (ERCP) or Percutaneous Transhepatic Cholangiography (PTC)
- No metastatic disease, including to regional lymph nodes
Who cannot take part
- Prior biliary resection or hilar dissection for attempted resection within the past 12 months
- Prior radiation to the upper abdomen
- Extrahepatic disease at any stage of presentation, assessment and treatment
- Prior malignancy in the last 5 years (excluding early breast, prostate, cervix and non melanoma skin cancers); Specific criteria
- Uncontrolled infection
- Estimated Glomerular Filtration Rate (eGFR) <30
- General criteria
- Inability to consent
- Poor performance status
- Failed fitness assessment
- Duodenal invasion
Where in United Kingdom
- University College London Hospitals NHS Foundation TrustLondon, United KingdomContact: Romelie RieuTaking people
- The Christie NHS Foundation TrustManchester, United KingdomContact: Romelie RieuTaking people
About the trial
What the trial wants to find out
Proton Beam Therapy (PBT) is an advanced radiotherapy technique. There are two National Health Service (NHS) PBT treatment centres in the United Kingdom (UK), in Manchester and London. The NHS is committed to ensuring the best use of this limited resource by investigating which patients will benefit from PBT.
Read full original descriptionShow less
Evaluative Commissioning in Protons (ECIP) is a programme of studies exploring the role of PBT in different types of cancer. The studies are funded by NHS England. ECIP studies are not randomised studies, which means that all eligible patients will be offered PBT. Any eligible patient in the UK can be referred, and accommodation is available for patients who don't live close to a PBT centre.
The main benefit of PBT, compared with standard photon radiotherapy, is the predicted reduction in radiation dose to surrounding healthy tissues. With photon radiotherapy, some radiation passes beyond the target area, affecting healthy tissues and causing side-effects. With PBT, the radiation dose stops within the target area, causing less damage to surrounding tissues, and limiting side effects.
EMPHATIC is a study within the ECIP programme. In EMPHATIC, the investigators are looking to see whether a combination of treatments, including PBT, chemotherapy and a liver transplant, can be used to treat patients with cholangiocarcinoma (bile duct cancer).
EMPHATIC offers patients whose cancer can't be removed with surgery (unresectable) a potentially curative treatment option. There is evidence that liver transplant is a curative treatment option in patients with cholangiocarcinoma. There is a risk that the cancer may grow or spread whilst waiting for a transplant, potentially making patients ineligible. PBT and chemotherapy is thought to be the best way to control the cancer, until a liver transplant can be performed. EMPHATIC will look at how a combination of PBT and chemotherapy, followed by a liver transplant, can be used to curatively treat patients with unresectable cholangiocarcinomas.
The group in the trial
- Proton Beam TherapyTreatment being tested
All patients to be offered neoadjuvant proton beam therapy to a dose of 45 Gray (Gy) in 15 fractions over 3 weeks, with a tumour boost to 67.5 Gray (Gy), and alongside concurrent oral capecitabine 625mg/m2 twice daily on radiation days.
Treatment: Proton Beam Therapy, Concurrent oral capecitabine chemotherapy, Cisplatin & Gemcitabine intravenous chemotherapy, and Orthotropic Liver Transplant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma (an Evaluative Commissioning in Protons Study)
- Plain-language title
- Tests proton beam therapy, chemotherapy and liver transplant for bile duct cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 November 2026